KR20030078803A - 마커의 선택 - Google Patents

마커의 선택 Download PDF

Info

Publication number
KR20030078803A
KR20030078803A KR10-2003-0019839A KR20030019839A KR20030078803A KR 20030078803 A KR20030078803 A KR 20030078803A KR 20030019839 A KR20030019839 A KR 20030019839A KR 20030078803 A KR20030078803 A KR 20030078803A
Authority
KR
South Korea
Prior art keywords
portfolio
gene
seq
relationship
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2003-0019839A
Other languages
English (en)
Korean (ko)
Inventor
제이트코에팀
Original Assignee
오르토-클리니칼 다이아그노스틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 filed Critical 오르토-클리니칼 다이아그노스틱스, 인코포레이티드
Publication of KR20030078803A publication Critical patent/KR20030078803A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)
  • Peptides Or Proteins (AREA)
KR10-2003-0019839A 2002-03-29 2003-03-29 마커의 선택 Withdrawn KR20030078803A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36879002P 2002-03-29 2002-03-29
US60/368,790 2002-03-29

Publications (1)

Publication Number Publication Date
KR20030078803A true KR20030078803A (ko) 2003-10-08

Family

ID=27805329

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-0019839A Withdrawn KR20030078803A (ko) 2002-03-29 2003-03-29 마커의 선택

Country Status (10)

Country Link
US (2) US20030194734A1 (https=)
EP (1) EP1349104A3 (https=)
JP (1) JP2004163388A (https=)
KR (1) KR20030078803A (https=)
CN (1) CN1495272A (https=)
AR (1) AR039212A1 (https=)
AU (1) AU2003203529A1 (https=)
BR (1) BR0303080A (https=)
CA (1) CA2422309A1 (https=)
MX (1) MXPA03002865A (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080597A1 (en) * 2005-01-31 2006-08-03 Digital Genomics Inc. Markers for the diagnosis of lung cancer
KR100690250B1 (ko) * 2005-01-31 2007-03-12 디지탈 지노믹스(주) 폐암 진단용 마커

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1788083A4 (en) * 2004-08-02 2008-08-13 Banyu Pharma Co Ltd METHOD FOR THE ADOPTION OF MEDICAMENT SENSITIVITY AGAINST THE INHIBITOR CDK4
MX2007006441A (es) * 2004-11-30 2007-08-14 Johnson & Johnson Prognosis de cancer de pulmon.
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
US20070207467A1 (en) 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
SG144111A1 (en) * 2006-12-22 2008-07-29 Shares Advisors Llc X Portfolio selection for custom indices of public securities based on state of domicile of issuing company
ATE531725T1 (de) 2007-02-27 2011-11-15 Nuclea Biomarkers Llc Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen
US20090192045A1 (en) * 2008-01-22 2009-07-30 Yuqiu Jiang Molecular staging of stage ii and iii colon cancer and prognosis
US20110059464A1 (en) 2008-04-08 2011-03-10 Muraca Patrick J Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
CA2753916C (en) 2009-04-29 2020-08-25 Genomedx Biosciences Inc. Systems and methods for expression-based classification of thyroid tissue
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000347B (el) * 1988-12-21 1992-06-25 Ortho Diagnostic Systems Inc Μεθοδος παραγωγης νουκλεοτιδικων ανιχνευτων χρησιμοποιωντας ενα συμπληρωμα γεφυρωσεως.
US6350576B1 (en) * 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6401043B1 (en) * 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
US6714925B1 (en) * 1999-05-01 2004-03-30 Barnhill Technologies, Llc System for identifying patterns in biological data using a distributed network
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
US6353152B1 (en) * 1999-07-15 2002-03-05 Research Development Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080597A1 (en) * 2005-01-31 2006-08-03 Digital Genomics Inc. Markers for the diagnosis of lung cancer
KR100690250B1 (ko) * 2005-01-31 2007-03-12 디지탈 지노믹스(주) 폐암 진단용 마커
US7871774B2 (en) 2005-01-31 2011-01-18 Digital Genomics Inc. Markers for the diagnosis of lung cancer

Also Published As

Publication number Publication date
AR039212A1 (es) 2005-02-09
US20030194734A1 (en) 2003-10-16
BR0303080A (pt) 2004-02-17
EP1349104A2 (en) 2003-10-01
EP1349104A3 (en) 2004-01-02
US20100009371A1 (en) 2010-01-14
CA2422309A1 (en) 2003-09-29
JP2004163388A (ja) 2004-06-10
AU2003203529A1 (en) 2003-10-23
CN1495272A (zh) 2004-05-12
MXPA03002865A (es) 2004-08-11

Similar Documents

Publication Publication Date Title
KR20030078803A (ko) 마커의 선택
KR20030078799A (ko) 암 진단 패널
Bie et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression
JP5237076B2 (ja) 乳癌患者の診断および予後
AU2013266419B2 (en) NANO46 genes and methods to predict breast cancer outcome
US10266902B2 (en) Methods for prognosis prediction for melanoma cancer
JP5089993B2 (ja) 乳癌の予後診断
JP4913331B2 (ja) 結腸直腸癌の予後
JP2007049991A (ja) 乳癌の骨への再発の予測
EP2982985A1 (en) System for predicting prognosis of locally advanced gastric cancer
JP2008521412A (ja) 肺癌予後判定手段
JP2010502227A (ja) 生物学的経路の遺伝子発現分析を用いたリンパ節陰性の原発性乳がんの遠隔転移を予測する方法
JP2011509689A (ja) Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断
EP2419540B1 (en) Methods and gene expression signature for assessing ras pathway activity
KR20030078805A (ko) 유방암 예후 포트폴리오
JP2023504334A (ja) 肺がんの診断のためのバイオマーカー
US20050186577A1 (en) Breast cancer prognostics
JP2004344171A (ja) 乳癌予後予測法
JP2007508008A (ja) 乳癌診断に関する物質および方法
WO2010060055A1 (en) Predicting cancer risk and treatment success
CN118222713A (zh) 生物标志物在检测脑胶质瘤相关tls中的应用
WO2010143941A1 (en) Classification and risk-assignment of childhood acute myeloid leukaemia (aml) by gene expression signatures
EP1679382A2 (en) Panel of nucleic acid sequences for cancer diagnosis
Mansmann et al. Classification and prediction in pharmacogenetics–context, construction and validation
CN113278705A (zh) 检测口腔鳞癌的基于生物标志物的诊断产品及其应用

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000